P PRIMESTOCKFINDER.COM

RAC Shares Racura Oncology Ltd

WATCH ASX · ASX
$1.54 -6.69% Prices as of close 2026-10-27

Oncology pipeline optionality and upcoming data provide high-risk, high-reward potential.

Signal breakdown

  • ▸Clinical pipeline updates remain the primary value catalyst.
  • ▾Below 50-day MA (-20.95%)
  • ▾Near 52-week low (0.7% of range)

Is RAC a buy right now?

Trend: RAC is trading below the 50-day average (-19.17%), RSI 53 — neutral momentum, with a 3-month return of -19.17%.

Valuation & quality: Racura Oncology Ltd trades on forward P/E -15.1, price-to-book 8.39; fundamentals show net margin 0.0%, return on equity -42.3%, revenue growth -12.2% year on year.

Our screen: WATCH (score 0) — Oncology pipeline optionality and upcoming data provide high-risk, high-reward potential.

Computed from end-of-day data; not personal advice.

12-month price chart

3.37 1.54 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-27 (AUD). Range 1.54 – 3.37.

Monthly returns

Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
+6.50%-0.80%-1.10%-14.00%-12.20%+9.20%-11.30%-17.50%

Fundamentals

Market cap
$305.9M
P/E (ttm)
-14.9
Forward P/E
-15.1
EPS (ttm)
$-0.06
Price / book
8.39
Beta
0.91
Net margin
0.0%
ROE
-42.3%
Revenue growth
-12.2%
Revenue (ttm)
$2.8M
Free cash flow
$-3,915,425
52-wk range
$1.52 – $3.79
Volume
51,839
Avg volume (3m)
79,315

Technical signals

RSI (14)
52.9
vs 50-day MA
-19.17%
1-mo return
-19.17%
3-mo return
-19.17%
Volume z-score
-0.25

About Racura Oncology Ltd

Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia.

Sector: Healthcare · Industry: Biotechnology · Australia · Website

Related Biotech picks

CSL.AXCSL LimitedMSB.AXMesoblast LimitedIMR.AXImricor Medical SystemSLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren PharmaceuticalsDXB.AXDimerix LimitedNYR.AXNyrada Inc.

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.